Blog
Alexion Acquires Voyager’s Preclinical Capsid for Rare Neurological Disease After $1B Pfizer Transfer
Pfizer has transferred an AAV capsid designed for a rare neurological disease target to AstraZeneca’s rare disease subsidiary, Alexion, as ...
Vertex Halts Phase 2 Lung Therapy, Reevaluates DMD Drug’s Clinical Path
Vertex Pharmaceuticals anticipates a “milestone-rich period” ahead, but there are updates regarding two of its candidates. The biotech has decided ...
Ventyx Halts TYK2 Inhibitor Despite Phase 2 Success, Stock Plummets 70%
Ventyx Biosciences discovered that even a seemingly successful clinical trial may not be enough to support a drug’s advancement, as ...
J&J MedTech Plans US Clinical Trials for Ottava Surgical Robot in Late 2024
Johnson & Johnson MedTech has set a new timeline for the development of its highly anticipated entry into the competitive ...
Imbria Pharmaceuticals Clears Safety Hurdles in Phase 2 Heart Failure Trial, Paving the Way for Promising Late-Stage Development
Imbria Pharmaceuticals has achieved positive results in a phase 2 trial for its heart failure medication. The Boston-based biotech, in ...
Zimmer Biomet Sees Steady Q3 Sales Growth, New CEO Tornos Unveils Vision for an ‘Innovation Journey’
Zimmer Biomet’s executive branch experienced significant changes in the third quarter, but these transitions haven’t derailed the company’s steady growth ...
Amgen’s deCODE Reveals New Clonal Hematopoiesis Risk Factors and Genes
Amgen’s subsidiary, deCODE Genetics, has uncovered new risk factors and genes associated with clonal hematopoiesis, a precursor condition to blood ...
Akeso’s Cadonilimab Achieves Significant Overall Survival in Severe Gastric Cancer Patients
Akeso’s bispecific antibody has demonstrated a significant improvement in overall survival for first-line patients with severe gastric cancer or gastroesophageal ...
WuXi XDC Plans $470.5M IPO to Drive Global Manufacturing Expansion
WuXi’s spinoff venture, WuXi XDC, is poised to make its debut on the Hong Kong Stock Exchange later this month, ...
NICE’s Rejection of Trikafta May Signal Price Dispute with Vertex in the UK
Vertex Pharmaceuticals faces a potential reiteration of history in the United Kingdom, where a recent decision by the National Institute ...
Krystal’s Vyjuvek Gene Therapy Gains FDA Approval, Spurs Sales Projections
Krystal Biotech’s CEO, Krish Krishnan, was quick to highlight in the company’s inaugural conference call to present its quarterly results ...
Vertex Gears Up for exa-cel Launch, Acknowledges Vast Opportunity with Cautious Outlook
After a prolonged journey in development, the first CRISPR-based gene editing therapy has recently received approval from an FDA advisory ...
Amgen’s Wezlana Emerges as Competitor to J&J’s Stelara, Shaping Medicare Negotiations
Johnson & Johnson may find a silver lining in the recent FDA approval of Amgen’s biosimilar for Stelara. This approval ...
Astellas’ Izervay Shows Prolonged Efficacy in 2-Year Study for Geographic Atrophy Treatment
Astellas made a significant acquisition of Iveric Bio earlier this year, primarily motivated by the potential of Iveric’s geographic atrophy ...
FDA Approves Neurovalens’ Modius Sleep Headset for Insomnia
The FDA has granted clearance to Neurovalens’ Modius Sleep device, offering a novel, drug-free solution for chronic insomnia in the ...
BMS Acquires Orum’s ADC ORM-6151 for AML and MDS Treatment
Bristol Myers Squibb (BMS) has made a significant move in the field of antibody-drug conjugates (ADCs) by acquiring Orum Therapeutics’ ...
MoonLake’s IL-17 Drug Gains Momentum with New Phase 2 Success
MoonLake Immunotherapeutics has achieved promising results in a phase 2 trial for its IL-17 inhibitor, sonelokimab, aimed at treating inflammatory ...
Kodiak’s Eye Drug Revival Spurs Renewed FDA Approval Bid
Kodiak Sciences had previously abandoned its tarcocimab tedromer program following disappointing results in two phase 3 trials. However, a recent ...
Congressional Inquiry into FDA Amidst Drug Shortages
As shortages of crucial medications, including amoxicillin, penicillin, Adderall, and certain chemotherapies, persist in the United States, two prominent Republican ...
October 2023 Layoff Tracker: Biotech & Pharma Sector Shifts
In the ebb and flow of the Biotech and Pharma sectors, workforce adjustments reflect not only individual corporate strategies but ...
Locanabio Announces Shutdown, Aids Staff in Job Transition
Locanabio is set to cease operations by the year’s end, succumbing to the challenging financial landscape that continues to affect ...
Lexeo Therapeutics Slashes IPO Price to Secure $100M Funding
Lexeo Therapeutics has revealed its intention to generate substantial capital through a Nasdaq listing, despite having recently scaled back its ...
CooperSurgical Finalizes Reduced Deal for Cook Medical OB-GYN Division
The recent transaction announcement by CooperSurgical may resonate with familiarity as the company has just completed an acquisition of certain ...
Pfizer Trims 200 Positions at Michigan COVID Plant During Cost-Saving Measures
The decline in demand for its COVID-19 treatments has prompted Pfizer to initiate a cost-reduction strategy across the company, which ...
Travere Fights for FDA Approval Despite Filspari’s Trial Endpoint Miss
Travere Therapeutics has recently encountered setbacks in two critical trials involving their drug Filspari, with implications for its accelerated approval ...
Court Rejects Alvogen’s Push for FDA Nod on Bausch’s Xifaxan Generic
Salix Pharmaceuticals, the gastroenterology division of Bausch Health, has successfully defended its irritable bowel syndrome diarrhea medication, Xifaxan, against a ...
Kronos Bio Slashes Staff by 19% to Fund Upcoming Solid Tumor Trial
Kronos Bio is undergoing a strategic reorganization, including a staff reduction of 19%, following promising early trial results for a ...
Lilly Expands Obesity Drug Range Amid Safety Trials
Eli Lilly is aggressively pursuing advancements in the field of obesity treatment, accelerating the development of an oral medication option ...
Moderna Reports $1.3B Loss and Cuts Back Production Amid Sales Dip
Moderna, once propelled to pharmaceutical prominence by its lucrative COVID-19 vaccine sales, now grapples with a decline in demand and ...
Novo Nordisk Q3 Sales Surge on GLP-1 Meds Amid Manufacturing Queries
Since the FDA gave the green light to Novo Nordisk’s GLP-1 weight-loss medication Wegovy over two years ago, the drug ...
